SG
VBIV

StoneX Group’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

StoneX Group’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-367
Closed -$4.3K – 834
2022
Q4 		$4.3K Buy
+367
New +$6.47K ﹤0.01% 607

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

StoneX Group's VBIV Position: Q1 2023 in Review

StoneX Group sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q1 2023, closing a stake of 367 shares — an estimated $4.3K sold.

StoneX Group first reported a position in VBIV in Q4 2022 and held it in 1 quarter. The position peaked at $4.3K in Q4 2022. 95 funds tracked by Wall St. Rank hold VBIV as of Q1 2023.

  • StoneX Group reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q1 2023 after selling out during the quarter.
  • StoneX Group sold 367 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q1 2023, an estimated $4.3K.
  • StoneX Group first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2022 and held it in 1 quarter.
  • StoneX Group's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $4.3K in Q4 2022.
  • 95 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.